[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521887":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Genoss Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"GENOSS Sirolimus Eluting Coronary Stent System",null,"Patients with coronary artery disease treated with the GENOSS DES\n\n\\\u003CDefinition of a complex high-risk patients\\>\n\n1. Clinical factors\n\n   * Age 75 or older\n   * History of diabetes (those who have had diabetes in the past or are taking diabetes medication)\n   * History of chronic kidney disease (GFR \\\u003C60ml\u002Fmin\u002F1.73m2) or dialysis\n   * History of stroke\n   * History of coronary artery bypass graft\n   * Left ventricular dysfunction (LVEF \\\u003C40%)\n   * Severe valve disease\n   * Acute coronary syndrome with positive troponin levels\n2. Lesion\u002Fprocedure factors\n\n   * Left main lesion\n   * Chronic total occlusion\n   * Bifurcation lesion with branches larger than 2 mm\n   * Calcified lesion (moderate to severe calcified lesion)\n   * Restenosis lesion (in-stent restenosis)\n   * Multivessel PCI\n   * Three or more stents implanted (≥3 stents implanted)\n   * When the stent length of one lesion is more than 50 mm (total stent length \\>50 mm in a lesion)",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"YoungJin Youn","CONTACT","033-741-0910","younyj@yonsei.ac.kr",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":10,"country":24,"countryCode":10,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Wonju Severance Christian Hospital","RECRUITING","Wŏnju","Gangwon State","South Korea",{"type":26,"coordinates":27},"Point",[28,29],127.94528,37.35139,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":16,"phoneExt":10,"email":17},"Young Jin youn",{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100521887","efficacy-and-safety-of-1-year-duration-of-dapt-after-genoss-des-implantation-in-patients-with-coronary-artery-disease-according-to-the-complex-higher-risk-procedure-100521887",false,"NCT06075433","Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure","DAPTLong","Inclusion Criteria:\n\n1. Patients of 19 and over\n2. Patients with coronary artery disease treated with GENOSS SES\n3. Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants\n\nExclusion Criteria:\n\n1. Patients with cardiogenic shock at the time of hospitalization\n2. Patients who are pregnant or planning to become pregnant\n3. Patients with a life expectancy of less than 1 year\n4. Patients participating in randomized controlled trials using other medical devices\n5. Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)","ALL","19 Years",{"count":47,"type":48},1000,"ESTIMATED","12 Months","OBSERVATIONAL","The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.",[53,54,55],"Coronary Artery Disease","Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","2025-02-18",{"date":58,"type":59},"2025-02-21","ACTUAL",{"date":61,"type":59},"2022-05-13",{"date":63,"type":48},"2027-12-31",{"name":5,"class":6},1]